bluebird bio Announces September Investor Events

Audio By Carbonatix

SOMERVILLE, Mass.--(BUSINESS WIRE)--Aug 28, 2024--

bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will participate in fireside chats at the following upcoming investor conferences:

• 2024 Wells Fargo Healthcare Conference, Wednesday, September 4, at 12:45 p.m. ET at the Encore Boston Harbor, Everett, MA
• Morgan Stanley 22nd Annual Global Healthcare Conference, Thursday, September 5, at 5:35 p.m. ET at the New York Marriott Marquis, New York, NY

To access the live webcast of bluebird bio’s fireside chats, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcasts will be available on the bluebird bio website for 90 days following the events.

About bluebird bio, Inc.

bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days.

Founded in 2010, bluebird has been setting the standard for gene therapy for more than a decade—first as a scientific pioneer and now as a commercial leader. bluebird has an unrivaled track record in bringing the promise of gene therapy out of clinical studies and into the real-world setting, having secured FDA approvals for three therapies in under two years. Today, we are proving and scaling the commercial model for gene therapy and delivering innovative solutions for access to patients, providers, and payers.

With a dedicated focus on severe genetic diseases, bluebird has the largest and deepest ex-vivo gene therapy data set in the field, with industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward.

bluebird continues to forge new paths as a standalone commercial gene therapy company, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds.

View source version on businesswire.com:https://www.businesswire.com/news/home/20240828846235/en/

CONTACT: Investors:

Courtney O’Leary, 978-621-7347

[email protected]:

Jess Rowlands, 857-299-6103

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: BIOTECHNOLOGY GENERAL HEALTH HEALTH GENETICS CLINICAL TRIALS

SOURCE: bluebird bio, Inc.

Copyright Business Wire 2024.

PUB: 08/28/2024 08:00 AM/DISC: 08/28/2024 08:02 AM

http://www.businesswire.com/news/home/20240828846235/en